Pfizer is the latest pharmaceutical giant to bet on gene therapies to cure intractable diseases
Pfizer Inc. has agreed to pay up to €560 million for the rights to gene therapies under development at French company Vivet Therapeutics, as it seeks to build its pipeline in this cutting-edge treatment.
The U.S. drugmaker said Wednesday it had paid €45 million upfront for a 15% stake in Vivet. Further payments, which include the potential acquisition of Vivet, are dependent on the progress of the French company’s experimental therapies.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Pfizer buys stake in French gene therapy firm VivetPfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.
और पढो »
Pfizer buys stake in French gene therapy firm VivetPfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.
और पढो »
Disney CEO Bob Iger takes big swing with Fox dealWalt Disney Co. officially acquires the 21st Century Fox assets, including the legendary movie and television studio, cable channels including FX and National Geographic,
और पढो »
Disney-Fox deal is complete; CEO Bob Iger's big swing could change media industryWalt Disney Co. officially acquires the 21st Century Fox assets, including the legendary movie and television studio, cable channels including FX and National Geographic,
और पढो »
For Mid-Majors, The NIT Is A Big DealThe NIT might be a source of derision for fans of big-time schools, but March's secondary college basketball tournament still matters to mid-major schools.
और पढो »
Democrats are taking reparations seriously -- and that's a big dealDemocrats are taking reparations seriously -- and that's a big deal | Analysis by CillizzaCNN
और पढो »
Analysis | The Energy 202: Labor opposition to Green New Deal could be a big obstacleAnalysis: Labor opposition to Green New Deal could be a big obstacle
और पढो »
Purdue Pharma CEO says bankruptcy is ‘an option’ as company faces opioid lawsuitsCraig Landau told The Washington Post that Purdue is developing a powerful anti-overdose drug in a pro-bono effort to combat the effects of the opioid crisis.
और पढो »
FDA medical adviser: 'Congress is owned by pharma'Despite many politicians, particularly declared presidential candidates, beginning to speak out against big pharma, an FDA medical adviser does not think that anything will come out of it “because Congress is owned by pharma.”
और पढो »